[go: up one dir, main page]

AR077630A1 - Polipeptidos y metodo de tratamiento - Google Patents

Polipeptidos y metodo de tratamiento

Info

Publication number
AR077630A1
AR077630A1 ARP100102358A ARP100102358A AR077630A1 AR 077630 A1 AR077630 A1 AR 077630A1 AR P100102358 A ARP100102358 A AR P100102358A AR P100102358 A ARP100102358 A AR P100102358A AR 077630 A1 AR077630 A1 AR 077630A1
Authority
AR
Argentina
Prior art keywords
antigen binding
polypeptides
treatment method
binding proteins
present application
Prior art date
Application number
ARP100102358A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR077630A1 publication Critical patent/AR077630A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

Se proporciona en la presente memoria una proteína de union a antígeno aislada que comprende al menos un primer dominio variable de inmunoglobulina capaz de unirse a la ADAMTS5 humana. También se proporcionan proteínas de union a antígeno de la presente solicitud que son anticuerpos monoclonales, composiciones farmacéuticas que comprenden dichas proteínas de union a antígeno y métodos de tratamiento.
ARP100102358A 2009-07-02 2010-07-01 Polipeptidos y metodo de tratamiento AR077630A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22252109P 2009-07-02 2009-07-02
US24975709P 2009-10-08 2009-10-08

Publications (1)

Publication Number Publication Date
AR077630A1 true AR077630A1 (es) 2011-09-14

Family

ID=43411744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102358A AR077630A1 (es) 2009-07-02 2010-07-01 Polipeptidos y metodo de tratamiento

Country Status (21)

Country Link
US (1) US20120095193A1 (es)
EP (1) EP2449127A4 (es)
JP (1) JP2012531902A (es)
KR (1) KR20120098587A (es)
CN (1) CN102482700A (es)
AR (1) AR077630A1 (es)
AU (1) AU2010266272A1 (es)
BR (1) BR112012000025A2 (es)
CA (1) CA2766641A1 (es)
CL (1) CL2011003354A1 (es)
CO (1) CO6480976A2 (es)
CR (1) CR20120027A (es)
DO (1) DOP2011000404A (es)
IL (1) IL217292A0 (es)
MA (1) MA33387B1 (es)
MX (1) MX2012000055A (es)
PE (1) PE20120554A1 (es)
SG (1) SG177288A1 (es)
TW (1) TW201114436A (es)
UY (1) UY32752A (es)
WO (1) WO2011002968A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP3434691A1 (en) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012116260A1 (en) * 2011-02-24 2012-08-30 Glaxo Group Limited Methods of identifying a patient population
WO2013109829A1 (en) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anti-adamts4 antibodies and methods of treatment
HUE031089T2 (en) 2012-04-13 2017-06-28 Rottapharm Biotech Srl Anti-ADAMTS-5 antibody, derivatives and uses
DK3057992T3 (da) * 2013-10-15 2024-07-22 Genefrontier Corp Humant antistof mod aggrecanase-lignende adamts-arter til terapi af aggrecanase-relaterede sygdomme
WO2017019729A1 (en) * 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
EP3630818A1 (en) * 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
KR102752550B1 (ko) * 2017-06-02 2025-01-10 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
EP3630817A1 (en) * 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
US12129308B2 (en) * 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
JPWO2019093497A1 (ja) * 2017-11-09 2021-01-21 株式会社リボミック Ａｄａｍｔｓ５に対するアプタマー及びその使用
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
US12043672B2 (en) 2022-09-07 2024-07-23 Synoa Therapeutics, Llc Compositions comprising bispecific antibodies to human ADAMTS5 and nerve growth factor
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
JP2007525406A (ja) * 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法

Also Published As

Publication number Publication date
WO2011002968A3 (en) 2011-04-07
SG177288A1 (en) 2012-02-28
CO6480976A2 (es) 2012-07-16
MA33387B1 (fr) 2012-06-01
MX2012000055A (es) 2012-01-27
IL217292A0 (en) 2012-02-29
BR112012000025A2 (pt) 2015-09-08
CL2011003354A1 (es) 2012-07-20
PE20120554A1 (es) 2012-06-08
CR20120027A (es) 2012-05-16
UY32752A (es) 2011-01-31
KR20120098587A (ko) 2012-09-05
JP2012531902A (ja) 2012-12-13
CA2766641A1 (en) 2011-01-06
WO2011002968A2 (en) 2011-01-06
EP2449127A4 (en) 2013-01-16
US20120095193A1 (en) 2012-04-19
AU2010266272A1 (en) 2012-01-19
EP2449127A2 (en) 2012-05-09
TW201114436A (en) 2011-05-01
DOP2011000404A (es) 2012-04-15
CN102482700A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
AR077630A1 (es) Polipeptidos y metodo de tratamiento
CR20150095A (es) Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica
AR121002A2 (es) Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica
NZ745357A (en) Antigen binding proteins that bind pd-l1
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
IN2014MN00873A (es)
NZ701444A (en) Antibodies to matrix metalloproteinase 9
EA201100527A1 (ru) Биологические продукты
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
CR20140585A (es) Proteinas de union a antigeno st2
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PH12015500929A1 (en) Anti-campylobacter jejuni antibodies and uses therefor
MX2021007870A (es) Anticuerpos monoclonales especificos para la proteina quimerica l del virus de la parainfluenza humana (piv), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por piv.
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein

Legal Events

Date Code Title Description
FA Abandonment or withdrawal